Algernon Pharmaceuticals Announces Receipt of Refundable Tax Credit from Australian Clinical Research
November 16, 2020 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study
November 09, 2020 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment
January 17, 2020 06:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial
November 25, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, B.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development...
Algernon Pharmaceuticals Announces Short Form Prospectus Unit Offering
July 04, 2019 07:00 ET
|
Algernon Pharmaceuticals
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone
July 03, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
April 04, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN
February 19, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce...